http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-PI0306774-B1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1f861d7dfdde7b233339d4838364a8e8
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127
filingDate 2003-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a8fea1f5335e43bdf81807bc4c5f12b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c8faca1924acae99706dc2b0649d6d82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28665cbbcc85b5bb218990fbee237f48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f536b94b4f7413327a56e734c1336e28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d9f12b0bc81feb8f7410d72bbecff339
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_403b2efae3607d6fecfd48edf8e4ede7
publicationDate 2018-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber BR-PI0306774-B1
titleOfInvention PH-SENSITIVE LIPOSOMES OF CISPLATIN AND OTHER ANTINEOPLASTIC AGENTS AND THEIR OBTAINING PROCESS
abstract "Cisplatin ph-sensitive liposomes and other antineoplastic agents and their process for obtaining them." The present invention relates to cisplatin ph-sensitive liposome formulations and other antineoplastic agents included or not included in cyclodextrin and their respective processes for obtaining them. Phisensitive cisplatin liposomes and other antineaplastic agents may allow specific release of chemotherapy at the site affected by the tumor, eliminate and / or reduce its adverse effects and the emergence of treatment resistance as well as allow the adoption of multidrug therapy regimens with incompatible drugs. in unencapsulated form. The sensitive liposomes are composed of non-lamellar phase-forming phospholipids, derived from the cholesteral joint or not with a polyethylene glycol chain-attached phospholipid.
priorityDate 2003-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID65082
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3283
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419572499
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID14049689
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415732167
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID444913
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419535155
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID441203
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID14798
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5453
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID421462122
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559261
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24785025
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419481811
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419507953
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419563898
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5997
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426208976
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419582371
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID15061530
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID444041
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419583841
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID152743293
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5287407
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419540045
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6437392
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID409060395
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419536599

Total number of triples: 44.